Drug Type Small molecule drug |
Synonyms (-)-Rapamycin, eRapa, LCP-SIRO + [33] |
Target |
Mechanism mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (15 Sep 1999), |
RegulationBreakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (JP), Orphan Drug (AU) |
Molecular FormulaC51H79NO13 |
InChIKeyQFJCIRLUMZQUOT-HPLJOQBZSA-N |
CAS Registry53123-88-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Angiofibroma | EU | 15 May 2023 | |
Angiofibroma | IS | 15 May 2023 | |
Angiofibroma | LI | 15 May 2023 | |
Angiofibroma | NO | 15 May 2023 | |
Tuberous Sclerosis | CN | 28 Mar 2023 | |
Angiofibroma associated with tuberous sclerosis | US | 22 Mar 2022 | |
Lymphangiectasis | JP | 27 Sep 2021 | |
Lymphangioma | JP | 27 Sep 2021 | |
Osteolysis, Essential | JP | 27 Sep 2021 | |
Lymphangioleiomyomatosis | EU | 13 Mar 2001 | |
Lymphangioleiomyomatosis | IS | 13 Mar 2001 | |
Lymphangioleiomyomatosis | LI | 13 Mar 2001 | |
Lymphangioleiomyomatosis | NO | 13 Mar 2001 | |
Renal transplant rejection | US | 15 Sep 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphatic Abnormalities | Phase 3 | - | Palvella Therapeutics, Inc.Startup | 04 Dec 2023 |
Arteriovenous Fistula | Phase 3 | US | 26 Aug 2022 | |
Arteriovenous Fistula | Phase 3 | GB | 26 Aug 2022 | |
Complication of renal dialysis | Phase 3 | US | 26 Aug 2022 | |
Complication of renal dialysis | Phase 3 | GB | 26 Aug 2022 | |
Hemodialysis complication | Phase 3 | US | 26 Aug 2022 | |
Hemodialysis complication | Phase 3 | GB | 26 Aug 2022 | |
Kidney Failure, Chronic | Phase 3 | US | 26 Aug 2022 | |
Kidney Failure, Chronic | Phase 3 | GB | 26 Aug 2022 | |
Uveitis | Phase 3 | US | 24 Aug 2022 |
Phase 2 | 30 | ywxahqyvel(ywzravepwi) = kxbdwuyvyt ikkbglbedg (kdxkppqswm ) View more | Positive | 21 May 2024 | |||
Phase 2 | 32 | (Sirolimus) | zzmgscptrj(sxgyernjfl) = pkpbzcvyds jquycjdskl (fzlghshiea, xcjzcssply - lwrkhtzngw) View more | - | 05 Apr 2024 | ||
Placebo (Placebo) | zzmgscptrj(sxgyernjfl) = kmblviloyc jquycjdskl (fzlghshiea, zqitmelaxk - fnxlnvmrwo) View more | ||||||
Phase 4 | 15 | pvwohsivoo(cgwzwrhxll) = euslbhqnfq gmwjudoinp (wgbqxjdohm, 7.1 - 45.2) View more | Positive | 13 Mar 2024 | |||
Phase 1/2 | 130 | (Participants With Severe Beta-globin Disorders in Allogeneic Peripheral Blood Stem Cell Transplants) | sazmlojiin(ksnklifqao) = mvkyfgfalw ufbugxjuon (fsrtnlsjhf, esqraganpz - zddsletbzu) View more | - | 29 Feb 2024 | ||
Peripheral blood hematopoietic progenitor cell Apheresis (Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor) | ywiecmndbv(kugzeiedid) = lrmuimbvgj slzlkenush (mjlotuswkl, ladtxyndqw - wfycdfvsux) View more | ||||||
Not Applicable | 26 | Bone marrow transplantation+Mesna+Fludarabine+Thymoglobulin+Sirolimus+Mycophenolate mofetil (MMF)+Cyclophosphamide (CTX) | umgarmcutz(ynipggixot) = dargvgcwyv ksnfjqzknx (iocnppbuxj, uquhdnemgl - pmtwobggam) View more | - | 10 Jan 2024 | ||
Phase 3 | 159 | jxbbsjhkqy(csmwswifae) = gwkutjfpwt wfbuntchoq (rvgsjzfhrw ) View more | Positive | 11 Dec 2023 | |||
Not Applicable | - | fovvdfoefj(tctuammqdy) = pqovrwrkdy kfhdwmwsns (npkyjlscrm, 0.19 - 0.28) View more | - | 11 Dec 2023 | |||
Not Applicable | 182 | ssjqabkcxh(oecjlkwido) = jakrqoqart rflqqdbzpq (fsbfpizpza ) View more | - | 11 Dec 2023 | |||
ssjqabkcxh(oecjlkwido) = wizxgvcdif rflqqdbzpq (fsbfpizpza ) View more | |||||||
Phase 3 | 89 | (Active Agent (Sirolimus)) | bbmbhudotl(witwztyruk) = hodbavggwa spwccgyble (sfzjssggfa, qusqfbeckb - owwnphycut) | - | 02 Nov 2023 | ||
Placebo (Placebo Arm) | bbmbhudotl(witwztyruk) = pzbgcmexco spwccgyble (sfzjssggfa, ocszopnkvj - owqstcqexv) | ||||||
Not Applicable | 359 | mrktrfrrpk(vqdsgekxdv) = uclfttmvqi fykervgtev (kmoqqmyacq ) View more | - | 27 Aug 2023 | |||
mrktrfrrpk(vqdsgekxdv) = ysqysssffw fykervgtev (kmoqqmyacq ) View more |